《Nature,4月2日,Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-03
  • Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic

    Timothy P. Hanna, Gerald A. Evans & Christopher M. Booth

    Nature Reviews Clinical Oncology (2020)

    During the COVID-19 global pandemic, the cancer community faces many difficult questions. We will first discuss safety considerations for patients with cancer requiring treatment in SARS-CoV-2 endemic areas. We will then discuss a general framework for prioritizing cancer care, emphasizing the precautionary principle in decision making.

  • 原文来源:https://www.nature.com/articles/s41571-020-0362-6
相关报告
  • 《Nature,4月2日,The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-03
    • The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic Philip C. Robinson & Jinoos Yazdany Nature Reviews Rheumatology (2020) The global COVID-19 pandemic has the potential to severely affect those with rheumatic diseases or who are taking immunosuppressive therapies. Information is lacking as to how these groups will fare if they become infected. A global alliance has rapidly formed to try to address this information deficit.
  • 《Nature,4月3日,Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-04
    • Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic Andrew M. South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath & Matthew A. Sparks Nature Reviews Nephrology (2020) The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.